TCI Wealth Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

TCI Wealth Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,071	Closed	-$4.37K	–	2422
2023 Q1	$4.37K	Hold	1,071	–	–	﹤0.01%	1621
2022 Q4	$5.38K	Buy	+1,071	New	+$6.71K	﹤0.01%	1475
2021 Q4	–	Sell	-140	Closed	-$3K	–	2578
2021 Q3	$3K	Buy	+140	New	+$3.08K	﹤0.01%	2055
2020 Q4	–	Sell	-137	Closed	-$2K	–	1700
2020 Q3	$2K	Hold	137	–	–	﹤0.01%	1214
2020 Q2	$3K	Hold	137	–	–	﹤0.01%	993
2020 Q1	$2K	Buy	137 +19	+16%	+$310	﹤0.01%	1140
2019 Q4	$2K	Buy	118 +90	+321%	+$1.32K	﹤0.01%	1242
2019 Q3	$0	Buy	+28	New	+$420	﹤0.01%	1666

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TCI Wealth Advisors's NGM Position: Q2 2023 in Review

TCI Wealth Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 1,071 shares — an estimated $4.37K sold.

TCI Wealth Advisors first reported a position in NGM in Q3 2019 and held it in 8 quarters. The position peaked at $5.38K in Q4 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

TCI Wealth Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 1,071 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $4.37K.
TCI Wealth Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
TCI Wealth Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.38K in Q4 2022.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.